logo for TRACON Pharma

TRACON Pharma

Business Services · California, United States · <25 Employees

View Company Info for Free

About

Headquarters

4350 La Jolla Village Dr Ste 800, San Diego, Ca...

Phone Number

(858) 550-0780

Revenue

$12.1 Million

Stock Symbol

TCON

Industry

Drug Manufacturing & Research Pharmaceuticals Healthcare

Who is TRACON Pharma

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for canc er, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. The companys other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development products include TRC205, an endoglin antibody for the treatment of fibrotic diseases; and TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694; and a license agreement with Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122, the ophthalmic formulation of TRC105, for ophthalmology indications. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego.Read more

TRACON Pharma's Social MediaPopular SearchesTracon Pharmaceuticals IncTRACON PharmaceuticalsTRACON Pharmaceuticals| IncPharma Mobilis BtTRACON IncSIC Code 87,873NAICS Code 54,541Ticker NASDAQ: TCONShow more

TRACON Pharma Org Chart

PhoneEmail
Patricia Bitar

Chief Financial Officer

PhoneEmail
James Freddo

Chief Medical Officer

PhoneEmail

PhoneEmail

Is TRACON Pharma your ideal costumer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Similar Companies to TRACON Pharma

  1. <25
    $8M

    1

  2. undefined
    $12.7M

    2

  3. undefined
    <$5M

    3

  4. <25
    <$5M

    4

  5. 51
    <$5M

    5

  6. <25
    $5.6M

    6

See more similar companies
Illustration of an envelope

TRACON Pharma Tech Stack

A closer look at the technologies used by TRACON Pharma

Top Companies in United States

Top 10 companies in United States by revenue

Top 10 companies in United States by number of employees

Top 10 companies in United States by total funding amount

See top companies

Most Recent Scoops

May 20 2024
Earnings
Partnership
May 20 2024
Earnings
Product Marketing, Product Development, Product Launch, Product Management, Sales, Sales Development
May 20 2024
Earnings
May 20 2024
Earnings
Upgrade, Data Center, Data Management, Data Warehousing
May 20 2024
Earnings
See more scoops

TRACON Pharma News & Media

Read more news

Frequently Asked Questions Regarding TRACON Pharma

Where is TRACON Pharma located?
TRACON Pharma's headquarters are located at 4350 La Jolla Village Dr Ste 800, San Diego, California, 92122, United States
What is TRACON Pharma's phone number?
TRACON Pharma's phone number is (858) 550-0780
What is TRACON Pharma's stock symbol?
TRACON Pharma's stock symbol is TCON
What is TRACON Pharma's official website?
TRACON Pharma's official website is www.traconpharma.com
What is TRACON Pharma's Revenue?
TRACON Pharma's revenue is $12.1 Million
What is TRACON Pharma's SIC code?
TRACON Pharma's SIC: 87,873
What is TRACON Pharma's NAICS code?
TRACON Pharma's NAICS: 54,541
How many employees does TRACON Pharma have?
TRACON Pharma has <25 employees
What industry does TRACON Pharma belong to?
TRACON Pharma is in the industry of: Drug Manufacturing & Research, Pharmaceuticals, Healthcare
What is TRACON Pharma competition?
TRACON Pharma top competitors include: Arca Biopharma, TARIS Biomedical, EiRx Therapeutics, Soligenix
What technology does TRACON Pharma use?
Some of the popular technologies that TRACON Pharma uses are: WordPress.org, Drupal, reCAPTCHA, PHP
Who is the CFO of TRACON Pharma?
TRACON Pharma's CFO is Patricia Bitar
How do I contact TRACON Pharma?
TRACON Pharma contact info: Phone number: (858) 550-0780 Website: www.traconpharma.com
What does TRACON Pharma do?

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase... II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. The companys other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development products include TRC205, an endoglin antibody for the treatment of fibrotic diseases; and TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694; and a license agreement with Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122, the ophthalmic formulation of TRC105, for ophthalmology indications. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego.Read More

What are TRACON Pharma social media links?
TRACON Pharma Linkedin page
Is TRACON Pharma a public company?
Yes, TRACON Pharma is a public company and is traded under the symbol TCON
See more information about TRACON Pharma

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.